Viatris’ Interchangeable Semglee Lands On Express Scripts Formulary
Company To Adopt ‘Dual Product Approach’ With Authorized Version
Executive Summary
Months after obtaining the first US FDA designation of interchangeability, for its Semglee biosimilar to Sanofi’s Lantus, Viatris has seen a return on its investment, with the biosimilar scooping preferred status on one of the largest national formularies in the US.
You may also be interested in...
Another PBM Favors Sandoz And Boehringer On Adalimumab
Express Scripts has followed Optum Rx’s lead by awarding preferred status to Humira biosimilars from Sandoz and Boehringer Ingelheim.
Lilly Gets Second Interchangeable Insulin Glargine In US
Eli Lilly has been granted an interchangeability designation by the US FDA for its Rezvoglar insulin glargine biosimilar, matching the designation previously granted for Viatris’ Semglee.
Labels The Issue For Viatris Again As It Recalls Insulin Glargine Biosimilar
A further voluntary recall for Viatris’ insulin glargine biosimilar, this time for one of its recently launched interchangeable products, because of missing labels may draw unwanted interest from the US FDA, a leading analyst has warned.